Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab 200mg

DRUG

Apatinib

Apatinib 250mg

DRUG

S-1, Oxaliplatin

S-1, Oxaliplatin, q3w

Trial Locations (3)

Sichuan Cancer Hospital & Institute, Chengdu

Changhai Hospital, Shanghai

Yantai Yuhuangding Hospital, Yantai

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT06693128 - Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer | Biotech Hunter | Biotech Hunter